Inhibikase Therapeutics (IKT) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($324.9 million vs $265.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IKT | SCTX |
|---|---|---|
| Share price | $1.90 | $17.16 |
| Market cap | $265.12M | $324.87M |
| 1-day change | -2.06% | -2.32% |
| YTD return | -5.37% | — |
| 1-year return | +19.75% | — |
| 5-year return | -83.25% | — |
| EPS (TTM) | $-0.43 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $39.60 |
| 52-week low | $1.33 | $13.50 |
| Distance from 52-week high | -27.20% | -56.67% |
| Analyst consensus | none | none |
| Avg. price target upside | +215.79% | +232.17% |
| Average volume | 656.02K | 357.50K |
| Shares outstanding | 139.54M | 18.93M |
| Employees | 35 | 82 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
IKT vs SCTX FAQ
Which is bigger, Inhibikase Therapeutics or Scribe Therapeutics?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $324.87M compared with $265.12M for Inhibikase Therapeutics (IKT).
Are Inhibikase Therapeutics and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.